Related Experiment Videos
[Arrhythmogenic right ventricular dysplasia. A new clinical entity]
G Fontaine1, F Fontaliran, R Frank
1Centre de Rythmologie et de Stimulation Cardiaque, Hôpital Jean Rostand, Ivry.
Bulletin De L'Academie Nationale De Medecine
|March 1, 1993
Summary
Arrhythmogenic right ventricular dysplasia (ARVD) is a heart muscle disease affecting young adults, often athletes. Early diagnosis and treatment, including antiarrhythmic drugs or interventions, are crucial for a good prognosis.
Area of Science:
- Cardiology
- Genetics
- Immunology
Context:
- Arrhythmogenic right ventricular dysplasia (ARVD), identified in 1977, primarily affects the right ventricular muscle.
- It is increasingly recognized as a form of cardiomyopathy, predominantly impacting young adults, including athletes.
- Patients often present with a nearly normal cardiac examination despite the risk of serious arrhythmias.
Purpose:
- To summarize the current understanding of arrhythmogenic right ventricular dysplasia (ARVD).
- To discuss the potential physiopathogenic mechanisms, clinical presentation, and management strategies for ARVD.
- To highlight the need for further clinical and basic science research.
Summary:
- ARVD is a disease of the right ventricle with unknown etiology, affecting young adults and athletes.
- Symptoms include ventricular arrhythmias leading to palpitations, syncope, or sudden death, which can be the initial sign.
- Potential causes include hereditary factors or post-myocarditis immunological responses.
- Treatment involves antiarrhythmic drugs, with options like ablation, defibrillators, surgery, or transplantation for resistant cases.
- With appropriate treatment, ARVD generally has a favorable prognosis.
Impact:
- Provides a concise overview of ARVD for clinicians and researchers.
- Emphasizes the importance of early diagnosis and management in young athletes.
- Underscores the need for continued research into the causes and optimal treatment of ARVD.